Detecting Pathological Cartilage Turnover via COMP Neoepitopes
Solution Overview
Problem
Current methods for diagnosing and monitoring cartilage degeneration, such as arthritis, face challenges in distinguishing between pathological and normal cartilage turnover due to high background levels from normal tissue turnover, leading to overlapping results between disease and non-disease patients.
Innovation Solution
The method involves detecting specific neoepitopes formed by cleavage of Cartilage Oligomeric Matrix Protein (COMP) at specific sites, such as positions 77-78, 88-89, 104-105, and others, which are not present in normal cartilage turnover, allowing for the differentiation between pathological and benign cartilage turnover.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If COMP or nucleic acid sequences encoding COMP are used as a marker of cartilage turnover, then cartilage turnover can be monitored, but it is not possible to distinguish between pathological and normal cartilage turnover due to high background levels from normal turnover
Solution Approach 1:
The invention segments the COMP protein into specific fragments by identifying cleavage sites at defined positions in the amino acid sequence. By detecting specific fragments (e.g., N-terminal fragments from positions 1-76, 1-87, 1-89, 1-90, 1-103 or C-terminal fragments from positions 77-624, 88-624, 91-624, 105-624), the method distinguishes pathological turnover from normal turnover, as these specific fragments are not produced during normal physiological processes.
Solution Approach 2:
The invention extracts specific neoepitopes or peptide sequences from the full COMP protein that are uniquely produced during pathological degradation. By focusing detection efforts on these specific extracted sequences (such as neoepitopes created at cleavage sites), the method eliminates the confounding background signal from normal COMP turnover while maintaining sensitivity to pathological processes.
2Reliability
If traditional diagnostic methods based on inflammation measures and autoantibodies are used, then diagnosis can be performed, but the results show great overlap between disease and non-disease patients
Solution Approach 1:
The invention applies local quality by targeting specific local regions (cleavage sites) within the COMP protein structure. Instead of measuring overall COMP levels or general inflammation markers, the method detects specific local changes in COMP fragmentation patterns at defined positions, providing localized information that is specific to pathological degradation processes and not present in normal turnover or healthy individuals.
3Loss of time
If early detection of pathological cartilage degeneration is pursued, then permanent tissue damage can be minimized, but current methods cannot reliably detect early stages due to high background from normal turnover
Solution Approach 1:
The invention performs preliminary action by identifying and characterizing specific cleavage sites and fragmentation patterns that occur early in pathological processes. By establishing these specific markers in advance (defining cleavage positions and corresponding neoepitopes), the method enables early detection before significant tissue damage occurs, as these specific fragments appear early in the pathological cascade and are not confounded by normal turnover background.
Data Source
AI summary
The present embodiments relate to methods for determining or detecting pathological cartilage turnover by detection of Cartilage Oligomeric Matrix Protein (COMP) neoepitopes, both released into body fluids and present in the tissue. Furthermore the embodiments relate to antibodies against COMP neoepitopes and to fragments and peptides containing COMP neoepitopes for generation of such antibody.